March 15, 2024 · Form 4 insider transaction
Levitz Michael L bought 51,682 shares of Anika Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Represents a 10% premium above the closing price of Anika's common stock on the date of grant.; The premium priced stock options vest in three equal annual installments beginning on March 15, 2025.